
Long-term clinical and patient reported outcomes of an

enhanced monofocal intraocular lens

1



Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Purpose: To evaluate long-term clinical and patient-reported outcomes (PROMs) following the implantation of an enhanced monofocal intraocular lens (IOL). Methods: This ambispective non-comparative single-centre study involved 41 patients (ages 48-84) who underwent bilateral cataract surgery with the Tecnis Eyhance IOL (model ICB00, Johnson & Johnson Vision). Distance and intermediate visual acuities, refraction, and PROMs were assessed 18 months or more after surgery. Spectacle independence was evaluated using the PRSIQ questionnaire, with patients self-reporting on visual quality, difficulties in performing specific tasks and perception of photic phenomena at distance and intermediate vision. Results: At 18 months or later, 100.0%, 73.2%, 100% and 79.5% of patients achieved a binocular uncorrected distance, uncorrected intermediate, corrected distance, and distance-corrected intermediate visual acuity of 0.20 logMAR or better, respectively. Less than 10% of patients reported photic phenomena. Mean visual quality scores were 1.68±0.72 for distance and 2.05±0.92 for intermediate vision (1=very good to 6=very poor). The dashboard was clearly visible while driving for 95.1% of patients, while 45.0% could perform screen work without glasses; an additional 40.0% could do so with enlarged fonts. Complete spectacle independence was reported by 87.8% for distance vision, and 53.7% for intermediate vision. At least moderately satisfied were 90.2% with distance vision, 87.8% with intermediate vision, and 51.2% with near vision. Conclusions: The enhanced monofocal IOL ICB00 provides good long-term distance and intermediate visual quality, leading to considerable spectacle independence and patient satisfaction. Most patients required near vision correction.

Introduction

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Presbyopia-correcting IOLs can be categorized by their underlying opticalphysical properties into diffractive and non-diffractive IOLs. While diffractive IOLs split incoming light through surface discontinuities, non-diffractive IOLs bend light by surface curvature changes. Another way to categorize IOLs is the range of focus they offer. Full range of focus (FROF) IOLS cover vision from distance to near, including intermediate distances. Due to their typically diffractive technology, PROF IOLs may compromise visual experience through dysphotopsia. Partial range of focus (PROF) IOLs cover a partial spectrum of vision, typically extending from distance to intermediate, with some capacity for near vision. They may be diffractive and non-diffractive and create fewer visual compromises such as dysphotopsias. Most recently, Fernandez et al. offered a systematic approach to categorize IOL types based on the shape of the defocus curve: PROF IOLs were divided into narrow, enhanced and extended PROF IOLs¹. In 2018, the American National Standard Institute (ANSI) provided specific criteria to define enhanced depth of focus (EDOF) IOLs as IOLs that correct aphakia, with an extended range of focus above a defined functional visual acuity threshold of 0.2 LogMAR, providing useful distance and intermediate vision with monotonically decreasing visual acuity from the best distance focal point.² With the introduction of a new technology named Tecnis Eyhance (model ICB00, Johnson & Johnson Vision) in 2019, a new category of intraocular lenses (IOLs) was generated, popularly known as mono-EDOF, or enhanced monofocal IOLs.3 According to Fernandez et al1 this IOL would be classified as enhanced PROF. This IOL extends the depth of focus similarly to EDOF IOLs, but does not meet the four effectiveness end-points required to classify it as true EDOF lenses according to the criteria of the American National Standard Z80.35-2018 (ANSI).² Enhanced monofocal IOLs include some optical modifications to provide an efficacious correction for distance vision while providing an enhanced intermediate visual function. Various studies have been conducted to characterize the clinical performance and patient acceptance of the Eyhance IOL and other enhanced monofocal IOLs.³⁻⁵ Notably, no higher incidence of postoperative photic phenomena was reported with these IOLs compared to regular monofocal lenses.⁶

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

The Evhance ICB00 IOL has an aspherical posterior surface and a modified aspheric anterior surface with a continuous increase in power from the periphery to the center of the lens while maintaining the distance image quality. The overall lens design is refractive and leverages the geometry, material, and corneal spherical aberration correction features, with a higher order aspheric profile included on the anterior optic surface. As this lens is designed to retain the benefits of a monofocal IOL while adding intermediate vision, the ICB00 IOL is considered an "enhanced" monofocal IOL designed to provide improved intermediate vision. A variety of clinical studies have demonstrated that this IOL provides good distance visual acuity with enhanced intermediate visual acuity. 8-27 Specifically, enhanced monofocal IOLs provide comparable results in terms of distance vision compared to conventional monofocal IOLs.⁸⁻²⁷ However, the number of studies about patient-reported outcomes (PROMs), which reflect the real perception of the patient regarding the improvement achieved with the implantation of the IOL, is still limited.7,11,17,27 Furthermore, long-term real-world data is still scarce. Given that neuroadaptation and habituation are the basis for patient satisfaction with all refractive IOLs and that this process takes 6 months and longer, it is of particular interest to analyze patient-reported outcomes at long term. Also, to satisfactorily manage patient expectations, it is especially relevant to know the real level of spectacle independence achieved with this type of enhanced monofocal IOL. The aim of the current study was to evaluate the long-term clinical and patient-reported outcomes after the implantation of the enhanced monofocal IOL ICB00 with special emphasis on the achieved level of spectacle independence. In addition, patient satisfaction with this type of IOL in a real-world setting was analyzed.

Methods

Patients

This was an ambispective, non-comparative, single-centre study enrolling a total of 41 patients who underwent uncomplicated phacoemulsification bilateral cataract surgery with implantation of the enhanced monofocal IOL ICB00 and had a follow up visit of 18 months or longer. Recruitment stared on October 17,2023 and ended November 30th 2023. The last patient was examined on December 12th, 2023. Included were patients with both eyes having a corneal astigmatism below 0.75D, aged 45 or older, and visually significant cataract. Exclusion criteria included known systemic diseases with the potential of altering the outcome of the study, previous ocular surgery including refractive surgery, irregular astigmatism, zonular alterations that may affect IOL position and stability, active ocular disease, previous diagnosis of retinal pathologies and severe glaucoma, as defined by mean deviation deficits of more than 12 dB on visual fields.

Before inclusion in the study, each patient was informed in detail about the nature of the study, and written informed consent was given according to the tenets of the Declaration of Helsinki. Minors were not included in the study. This study was approved by the medical ethics committee of the Medical Chamber of North-Rhine, Germany (No: 2023012).

Clinical Protocol

All patients underwent a complete preoperative examination, including measurement of uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), objective refraction by autorefractometry, optical biometry and

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

keratometry (IOLMaster 700, Carl Zeiss Meditec), non-contact tonometry, slit lamp biomicroscopy, optical coherence tomography of the macula and optic disc (Carl Zeiss Meditec), and dilated fundus evaluation. In all cases, the Barrett TK formula was used for IOL power calculation, targeting emmetropia. Postoperatively, patients were evaluated at 1 day and later at the discretion of the referring physician. Eighteen months after cataract surgery, all patients were contacted by phone and/or email and scheduled for a long-term follow-up visit. At this visit, a complete visual evaluation was performed, including the following tests: monocular and binocular measurement of UDVA and CDVA, manifest refraction, and measurement of uncorrected intermediate visual acuity (UIVA) and distance-corrected intermediate visual acuity (DCIVA) (measured at 66 cm). Spectacle independence was evaluated using the Patient-Reported Spectacle Independence Questionnaire (PRSIQ).²⁸ We assessed the patientreported quality of vision and photic phenomena using a self-developed questionnaire, where patients quantified the level of distance and intermediate visual quality on a scale from 1 (excellent) to 6 (extremely poor). Additionally, patients were asked about the perception of halos, glare, blurring, and starbursts at distance and intermediate vision. Surgery

All surgeries were performed by two experienced surgeons (AM, KT) using a standard technique of sutureless microincision phacoemulsification. Before surgery, patients received a peribulbar block (4 mL 0.75% bupivacaine, 2 mL 2% mepivacaine and 75 IE hyaluronidase (ESTEVE Pharmaceuticals GmbH) and dilating eye drops (phenylephrine hydrochloride 5%, Ursapharm Arzneimittel GmbH; tropicamide 0.5%,

Pharma Stulln GmbH). Patients who were taking warfarin with a high international normalized ratio received topical anesthesia.

A clear corneal incision with a width of 2.4 mm was placed either superior or temporal as well as two paracenteses (1.0 mm). A manual capsulorhexis was performed under ophthalmic viscoelastic device (OVD). Care was taken to achieve a capsulorhexis diameter of approximately 5 mm to ensure complete coverage of the IOL optic with the anterior capsule. Nuclear disassembly and cortical aspiration were performed using the Centurion vision system (Alcon). The IOL was delivered either under irrigation or viscoelastic protection with an injector provided by the manufacturer. At the end of the procedure, 1 mg cefuroxime and 2mg dexamethasone [4 mg/mL] were administered intracamerally and subconjunctivally, respectively.

Postoperative treatment included a combination eye drop four times a day containing dexamethasone, neomycin sulfate, and polymyxin-B-sulfate with ointment at night or, in case of allergies to preservatives, ofloxacin and dexamethasone eyedrops four times a day. This treatment was tapered over 4 weeks.

Statistical analysis

Data analysis was performed using the software SPSS version 22.0 for Windows (SPSS). Normality of all data distributions was initially evaluated by means of the Kolmogorov-Smirnov test. A descriptive analysis of all continuous variables was carried out, calculating the average values with their corresponding standard deviations and the ranges of maximum and minimum values. For categorical variables, frequencies of different conditions or aspects were determined. A p-value below 0.05 was considered statistically significant.

Results

Patient population: A total of 82 eyes of 41 patients with a mean age of 69.4 years (SD: 9.0, median: 70.0, range: 48 to 84 years) was enrolled. The sample comprised 24 males (58.5%) and 17 females (41.5%).

Refractive outcomes: Table 1 summarizes the visual and refractive outcomes obtained at the last postoperative visit, more than 18 months after surgery: Mean postoperative binocular logMAR UDVA and UIVA values were 0.05 ± 0.07 and 0.18 ± 0.12, respectively.

	Right eye	Left eye	Binocular
VA (LogMar)	Mean (SD)	Mean (SD)	Mean (SD)
	Median (Range)	Median (Range)	Median (Range)
UDVA	0.11 (0.10)	0.10 (0.09)	0.05 (0.07)
	0.10 (0.00 to 0.30)	0.10 (0.00 to 0.30)	0.00 (0.00 to 0.20)
CDVA	0.05 (0.08)	0.04 (0.05)	0.02 (0.04)
	0.00 (0.00 to 0.30)	0.00 (0.00 to 0.20)	0.00 (0.00 to 0.10)
UIVA	0.27 (0.15)	0.24 (0.14)	0.18 (0.12)
	0.30 (0.00 to 0.70)	0.20 (0.00 to 0.60)	0.20 (0.00 to 0.50)
DCIVA	0.22 (0.13)	0.22 (0.13)	0.17 (0.11)
	0.20 (0.00 to 0.50)	0.20 (0.00 to 0.50)	0.20 (0.00 to 0.40)
SE (D)	0.06 (0.47)	0.19 (0.53)	
	0.00 (-0.75 to 1.13)	0.25 (-1.00 to 1.50)	

Table 1.- Long-term (18 months or longer) postoperative visual and refractive outcomes: CDVA, corrected distance visual acuity; DCIVA, distance-corrected intermediate visual acuity; SD, standard deviation; SE, spherical equivalent; UDVA, uncorrected distance visual acuity; UIVA, uncorrected intermediate visual acuity.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Likewise, a mean binocular logMAR DCIVA value of 0.17 ± 0.11 was measured. 100.0%, 73.2%, 100% and 79.5% of patients achieved a binocular UDVA, UIVA, CDVA and DCIVA of 0.20 logMAR or better, respectively (Figure 1). Figure 1.- Postoperative binocular visual acuity: uncorrected distance (UDVA). uncorrected intermediate (UIVA), corrected distance (CDVA) and distance-corrected intermediate (DCIVA). The postoperative spherical equivalent (SE) was within ± 0.50 D in 80.5% of right eyes and 82.9% of left eyes. Likewise, postoperative SE was within ±1.00 D in 95.1% and 92.7% of right and left eyes, respectively. Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2). Figure 2.- Perception of photic phenomena 18 months postoperatively. These percentages decreased to 2.4%, 2.4% and 4.9% for the perception of halos, blurry vision, and glare at intermediate vision, respectively (Figure 2). Analysis of this subgroup did not reveal a significantly increased refractive error.

The visual quality achieved at distance and intermediate vision was subjectively graded by the patients on a scale from 1 (very good) to 6 (very poor). This grading scale, adapted from the German school system, is widely accepted and familiar to patients. Mean distance and intermediate visual quality satisfaction scores were 1.68 (SD: 0.72; Median: 2.00; Range: 1 to 3) and 2.05 (SD: 0.92; Median: 2.00; Range: 1 to 4), respectively. No patient provided scores of 4 or worse when asked about satisfaction with distance and intermediate visual quality. A total of 95.1% of patients reported a clearly visible dashboard when driving a car. When the dashboard was brightly illuminated, an additional 97.5 % of patients reported clear visibility. 45% of patients were able to perform screen work without spectacles, 40% had to enlarge the font and 63.4% of patients achieved spectacle-free reading when the font size was large enough.

Regarding the level of spectacle independence in the past 7 days, most patients did not need spectacles for distance vision (87.8%) after surgery, whereas more than half of the sample evaluated did not need them for intermediate vision (53.7%) (Figure 3A).

Figure 3.- Outcomes obtained with the PRISQ questionnaire.

In contrast, most patients required glasses for near vision activities (97.6%) (Figure 3A). Furthermore, a total of 82.5% of patients did not wear glasses at any time for distance vision during the last 7 days, whereas this percentage decreased to 36.6% for intermediate vision (Figure 3B).

Concerning patient satisfaction, a total of 90.2%, 87.8%, 51.2% and 90.0% of patients were completely, mostly or moderately satisfied with their unaided distance, intermediate, near and overall vision, respectively (Figure 3C).

No adverse events were recorded during the follow-up, with no cases showing a development of posterior capsular opacification (PCO) requiring YAG capsulotomy.

Discussion

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

To the best of our knowledge this is the first study to demonstrate excellent distance and good intermediate visual acuities at long term after implantation of the ICB00. No adverse events were noted. Special emphasis was placed on patients' perception: photic phenomena were denied for distance or intermediate vision by over 90% of study participants. Furthermore, 75% of patients were completely or moderately satisfied with their overall vision. This is consistent with other studies evaluating the same IOL. 7,10,11,17,25,26 and other models of enhanced monofocal IOLs. 29,30 Goslings et al 11 reported mean binocular UDVA of 0.11 ± 0.11 , and UIVA of 0.12 ± 0.11 at three months. These visual results are slightly worse than those in our study, which could be explained by a different IOL calculation formula, not specified in the publication. Giglio et al. reported mean postoperative binocular UDVA, UIVA and DCIVA values of -0.03 ± 0.07 , 0.17 ± 0.12 and 0.13 ± 0.11 , in 30 eyes using the Barrett Universal II formula. Mencucci et al. also reported similar mean binocular UDVA, UIVA and DCIVA values (0.03 ± 0.05) vs. 0.16 ± 0.10 vs. 0.15 ± 0.08) in 80 eyes of 40 patients using the Holladay 1 formula for axial lengths between 22.0 mm and 25.0 mm and Hoffer Q formula for axial lengths equal to or less than 22.0 mm. Their axial length measurements were obtained using the IOL master 500 (Carl Zeiss Meditec AG)²⁶ However, other authors have reported worse UDVA and better UIVA values in eyes implanted with the ICB00 in which a micromonovision approach had been applied or a trend towards a low myopic residual refractive error was found. ICB00 allows for efficient restoration of distance visual acuity, with enhanced intermediate visual function.

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

Furthermore, we analyzed how this functional intermediate vision was perceived by patients. Specifically, we investigated the level of spectacle independence, perceived difficulties in daily vision-related tasks, and the perception of photic phenomena. Spectacle independence was evaluated using the PRSIQ questionnaire, a validated patient-reported measure assessing spectacle independence following cataract surgery.²⁸ To this date and to the best of our knowledge, our study is the first to report the level of spectacle independence achieved with the model ICB00 at 18 months or later. As is common after cataract surgery with the implantation of any conventional monofocal IOL, the level of spectacle independence at distance was high: 87.8% of patients were spectacle or contact lens free at any time of the day. However, for intermediate vision only 53.7% of patients were spectacle or contact lens free. On the other hand, when examining the degree of spectacle dependence for intermediate vision, only 21.9% of patients used spectacle correction all the time or most of the time. Regarding near vision, the level of spectacle dependence was significant, with 97.6% of patients wearing glasses for such purposes and 75.6% of them wearing them all the time or most of the time. Using the PRSIQ tool, Stodulka and Pracharova³¹ investigated another IOL with an optical principle comparable to the IOL type we tested, where a special geometry creates a power gradient from the centre to the periphery. Spectacle independence with this EDOF IOL was achieved in over 80% of patients at distance and intermediate vision. In our study, 90.2% of patients were satisfied with their uncorrected distance and 87.8% with their uncorrected intermediate vision. This confirms the ability of the enhanced monofocal IOL model ICB00 to provide satisfactory distance and intermediate visual outcomes. This is highly relevant since intermediate vision is essential for the use of computers or equivalent handheld electronic devices such as smartphones and tablets.³² Regarding near vision, despite the limitations in terms of visual acuity, approximately

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

half of the sample reported being satisfied with their near visual functionality. This can be explained by the visual acuity provided, which might allow a variety of near vision activities without spectacle correction. Indeed, reading activity after surgery was possible in 14.6% of patients without any additional optical aid, and 63.4% of patients were able to read without correction if font size was large enough. This finding is supported by studies by Goslings et al¹¹ and Giglio et al⁷, who used the validated questionnaire Catquest 9SF to investigate difficulties in performing different vision-related activities after the implantation of the ICB00 IOL and detected a trend towards improvement in Raschcalibrated scores of questions about near vision. Lopes et al¹⁷ evidenced significant differences between eyes implanted with a conventional monofocal IOL and those implanted with the model ICB00 in the level of difficulty in reading newspaper print and reading the prices of goods while shopping, with better outcomes in the group of eyes implanted with the enhanced monofocal IOL. In our sample, screen work could be performed postoperatively without correction by 45.0% of patients, with an additional percentage of 40.0% of patients able to do it without problems if the font was large enough. Likewise, 95.1% of patients could clearly see the dashboard while driving a car. These outcomes are consistent with those obtained with the validated questionnaire Catquest 9SF in other studies evaluating the ICB00, in which the benefit in intermediate vision with the enhanced monofocal IOL over a conventional monofocal was consistently perceived by patients.^{7,11,17} In accordance with all these PROMs, the level of visual quality graded subjectively by the patient for distance and intermediate vision was good or very good for all patients, with no patient reporting poor distance or intermediate visual quality. This was also consistent with a low percentage of patients perceiving photic phenomena, including halos, blurry vision, and glare, at distance and intermediate vision (less than 10% in all

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

cases). This aligns with optical simulations that demonstrated fewer halos with the enhanced monofocal IOL evaluated than with the other two types of extended range of vision IOLs.³³ Lee and colleagues³⁴ compared the enhanced monofocal IOL evaluated in the current study with a diffractive EDOF IOL and found that although spectacle independence was higher in the diffractive group, this was at the expense of more glare and halos. Similarly, Corbelli et al¹⁶ found that the enhanced monofocal IOL was not inferior to a diffractive IOL regarding intermediate visual outcome and spectacle independence but had the advantage of less perception of halos and glare. Limitations of our study include the lack of a control group with a monofocal IOL as well as data on corneal spherical aberration of the study patients. Given that neuroadaptation and habituation take 6 months and longer, this study provides important insights into patient-perceived outcomes at long term. In view of a growing array of FROF and PROF IOLs, long term data are very valuable to improve patient satisfaction and patient counselling. In conclusion, ICB00 provides excellent levels of distance and good intermediate visual quality, leading to satisfactory levels of spectacle independence and patient satisfaction at long term. Increased long-term side-effects or increased photic phenomena were not detected. Near visual outcome, however, was more limited and varied considerably among subjects.

References

316

- 317 1.- Fernández J, Ribeiro F, Rocha-de-Lossada C, Rodríguez-Vallejo M. Functional
- 318 Classification of Intraocular Lenses Based on Defocus Curves: A Scoping Review and
- 319 Cluster Analysis. J Refract Surg. 2024;40(2):e108-e116.
- 320 2.- American National Standard for Ophthalmics. ANSI Z80.35-2018: extended depth of
- focus intraocular lenses. 2018. Available at: .
- 3.- Fernández J, Rocha-de-Lossada C, Zamorano-Martín F, Rodríguez-Calvo-de-Mora
- 323 M, Rodríguez-Vallejo M. Positioning of enhanced monofocal intraocular lenses between
- 324 conventional monofocal and extended depth of focus lenses: a scoping review. BMC
- 325 Ophthalmol. 2023;23(1):101.
- 326 4.- Redruello-Guerrero P, Rivera-Izquierdo M, Jiménez-Gutiérrez C, Láinez-Ramos-
- Bossini AJ, Yela R, López-Marín I. Improvement of intermediate vision with new
- monofocal intraocular lenses: A systematic review and meta-analysis. Eur J Ophthalmol.
- 329 2023;33(3):1308-1319.
- 330 5.- Wan KH, Au ACK, Kua WN, Ng ALK, Cheng GPM, Lam NM, Chow VWS.
- 331 Enhanced Monofocal Versus Conventional Monofocal Intraocular Lens in Cataract
- 332 Surgery: A Meta-analysis. J Refract Surg. 2022;38(8):538-546.
- 333 6.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;
- 334 Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced
- intermediate function in patients with cataract. J Cataract Refract Surg. 2021 Feb
- 336 1;47(2):184-191. doi: 10.1097/j.jcrs.00000000000399. PMID: 32932369.
- 7.- Giglio R, Vinciguerra AL, Presotto M, Jonak K, Rejdak R, Toro MD, Nanavaty MA,
- Tognetto D. Visual outcomes and patient satisfaction after bilateral implantation of an
- enhanced monofocal intraocular lens: a single-masked prospective randomized study. Int
- 340 Ophthalmol 2024;44(1):112.

- 8.- Singh G, Sidhharthan KS, Reddy JK, Sundaram V, Thulasidas M. Comparison of
- visual outcomes in patients implanted with Tecnis Eyhance ICB00 and 1-Piece ZCB00
- monofocal intraocular lenses. Indian J Ophthalmol 2024;72(2):181-184.
- 9.- Negishi K, Masui S, Ayaki M, Torii H, Yotsukura E, Nishi Y. Clinical results and
- 345 factors affecting visual function in eyes implanted with an enhanced monofocal
- intraocular lens. Clin Ophthalmol 2023;17:3965-3973.
- 10.- Gigon E, Bouthour W, Panos GD, Pajic B, Massa H. Real world outcomes of the
- new Tecnis Eyhance IOL. Eur J Ophthalmol. 2023;33(3):1390-1397.
- 349 11.- Goslings O, Veraart H, van de Laar-Muskens J, Piñero DP. Clinical outcomes with
- an aspheric monofocal and a new enhanced monofocal intraocular lens with modified
- optical profile. Graefes Arch Clin Exp Ophthalmol. 2023;261(8):2315-2326.
- 352 12.- Beltraminelli, T., Rizzato, A., Toniolo, K, Galli A, Menghini M. Comparison of
- visual performances of enhanced monofocal versus standard monofocal IOLs in a mini-
- monovision approach. BMC Ophthalmol 2023;23(1):170.
- 13.- Choi WK, Han HJ, Son HS, Khoramnia R, Auffarth GU, Choi CY. Clinical outcomes
- of bilateral implantation of new generation monofocal IOL enhanced for intermediate
- distance and conventional monofocal IOL in a Korean population. BMC Ophthalmol
- 358 2023;23(1):157.
- 359 14.- Garzón N, Poyales F, Albarrán-Diego C, Rico-Del-Viejo L, Pérez-Sanz L, García-
- 360 Montero M. Visual and optical quality of enhanced intermediate monofocal versus
- 361 standard monofocal intraocular lens. Graefes Arch Clin Exp Ophthalmol.
- 362 2022;260(11):3617-3625.
- 363 15.- Steinmüller LN, Greve D, Rua Amaro D, Bertelmann E, von Sonnleithner C.
- Analysis of higher-order aberrations in relation to the clinical outcome of an enhanced
- 365 monofocal IOL. Eur J Ophthalmol 2023;33(6):2096-2105.

- 16.- Corbelli E, Iuliano L, Bandello F, Fasce F. Comparative analysis of visual outcome 366
- 367 with 3 intraocular lenses: monofocal, enhanced monofocal, and extended depth of focus.
- 368 J Cataract Refract Surg. 2022;48(1):67-74.
- 17.- Lopes D, Loureiro T, Carreira R, Rodrigues Barros S, Cardoso JN, Campos P, 369
- Machado I, Campos N. Comparative evaluation of visual outcomes after bilateral 370
- 371 implantation of an advanced or conventional monofocal intraocular lens. Eur J
- 372 Ophthalmol. 2022;32(1):229-234.
- 18.- Huh J, Eom Y, Yang SK, Choi Y, Kim HM, Song JS. A comparison of clinical 373
- outcomes and optical performance between monofocal and new monofocal with 374
- 375 enhanced intermediate function intraocular lenses: a case-control study. BMC
- Ophthalmol 2021;21(1):365. 376
- 377 19.- Ucar F, Cetinkaya S. The evaluation of a new IOL with extended depth of focus to
- 378 increase visual acuity for intermediate distance. SN Compr Clin Med. 2021;3:22852021;
- 3:2285-2291. 379
- 380 20.- Kang KH, Song MY, Kim KY, Hwang KY, Kwon YA, Koh K. Visual performance
- and optical quality after implantation of a new generation monofocal intraocular lens. 381
- Korean J Ophthalmol. 2021;35(2):112-119. 382
- 383 21.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;
- Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced 384
- 385 intermediate function in patients with cataract. J Cataract Refract Surg. 2021;47(2):184-
- 386 191.
- 22.- Cinar E, Bolu H, Erbakan G, Yuce B, Aslan F, Fece M, Emre S. Vision outcomes 387
- with a new monofocal IOL. Int Ophthalmol. 2021;41(2):491-498. 388

- 23.- Unsal U, Sabur H. Comparison of new monofocal innovative and standard 389
- 390 monofocal intraocular lens after phacoemulsification. Int Ophthalmol. 2021;41(1):273-
- 391 282.
- 392 24.- Yangzes S, Kamble N, Grewal S, Grewal SPS. Comparison of an aspheric monofocal
- 393 intraocular lens with the new generation monofocal lens using defocus curve. Indian J
- Ophthalmol. 2020;68(12):3025-3029. 394
- 25.- de Luis Eguileor B, Martínez-Indart L, Martínez Alday N, Sacristán Egüén C, 395
- Cuadros Sánchez C. Differences in intermediate vision: monofocal intraocular lenses vs. 396
- 397 monofocal extended depth of focus intraocular lenses. Arch Soc Esp Oftalmol (Engl Ed).
- 398 2020;95(11):523-527.
- 26.- Mencucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome, 399
- 400 optical quality, and patient satisfaction with a new monofocal IOL, enhanced for
- 401 intermediate vision: preliminary results. J Cataract Refract Surg. 2020;46(3):378-387.
- 27.- Nanavaty MA, Ashena Z, Gallagher S, Borkum S, Frattaroli P, Barbon E. Visual 402
- 403 acuity, wavefront aberrations, and defocus curves with an enhanced monofocal and a
- 404 monofocal intraocular lens: a prospective, randomized study. J Refract Surg
- 405 2022;38(1):10-20.
- 28.- Morlock R, Wirth RJ, Tally SR, Garufis C, Heichel CWD. Patient-Reported 406
- Spectacle Independence Questionnaire (PRSIQ): Development and Validation Am J 407
- Ophthalmol 2017; 178: 101-114. 408
- 29.- Ang RET, Stodulka P, Poyales F. Prospective randomized single-masked study of 409
- bilateral isofocal optic-design or monofocal intraocular lenses. Clin Ophthalmol 410
- 411 2023;17:2231-2242.

- 30.- Bova A, Vita S. Clinical and Aberrometric Evaluation of a New Monofocal IOL with 412
- 413 Intermediate Vision Improvement. Ophthalmol. 2022;2022:41196982022;
- 414 2022:4119698.
- 31.- Stodulka P, Pracharova Z. Evaluation of extended depth-of-focus hydrophobic 415
- intraocular lens with an optic concept based on combination of high-order aberrations. 416
- 417 Ther Adv Ophthalmol 2023 Oct 3:15:25158414231200108.
- 418 32.- Ribeiro F, Cochener B, Kohnen T, Mencucci R, Katz G, Lundstrom M, Casanovas
- AS, Hewlett D. Definition and clinical relevance of the concept of functional vision in 419
- cataract surgery ESCRS Position Statement on Intermediate Vision: ESCRS Functional 420
- 421 Vision Working Group. J Cataract Refract Surg. 2020;46 Suppl 1:S1: S1-S3.
- 33.- Azor JA, Vega F, Armengol J, Millan MS. Optical assessment and expected visual 422
- quality of four extended range of vision intraocular lenses. J Refract Surg. 423
- 424 2022;38(11):688-697.
- 34.- Lee JH, Moon SY, Chung HS, Park SY, Lee H, Kim JY, Tchah H. Clinical outcomes 425
- 426 of a monofocal intraocular lens with enhanced intermediate function compared with an
- extended depth-of-focus intraocular lens. J Cataract Refract Surg. 2022;48(1):61-66. 427




Figure 1






Figure 2








Figure 3